LSM

Avalon GloboCare Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company

Retrieved on: 
Monday, February 13, 2023
Toxicology, Laboratory, Pharmacogenomics, Celltech, LSM, Cyprus Securities and Exchange Commission, Pathology, National Health Laboratory Service, Genetic testing, STAT, Niche market, Earnout

FREEHOLD, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it has acquired a 40% interest in Laboratory Services MSO, LLC (“LSM”), a premier clinical diagnostics and reference laboratory. Headquartered in Costa Mesa, California, LSM provides a broad portfolio of diagnostic tests including drug testing, toxicology, pharmacogenetics, and a broad array of test services, from general bloodwork to anatomic pathology. Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more. LSM has a sophisticated and state-of-the-art facility for clinical diagnostics and reference laboratory. It has also developed a premier reputation for customer service satisfaction and fast turnaround time in the industry. LSM has completed over 600,000 tests since inception and currently has two operational locations in California.

Key Points: 
  • FREEHOLD, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it has acquired a 40% interest in Laboratory Services MSO, LLC (“LSM”), a premier clinical diagnostics and reference laboratory.
  • Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more.
  • LSM has a sophisticated and state-of-the-art facility for clinical diagnostics and reference laboratory.
  • It has also developed a premier reputation for customer service satisfaction and fast turnaround time in the industry.

Independent review by network analytics and simulation firm FNA reveals "powerful liquidity savings" generated by CHIPS settlement algorithm

Retrieved on: 
Wednesday, February 1, 2023
CHIPS, Private sector, School corporal punishment, Clearing house, FNA, Literature, Leg, LSM, Senior, USD, New product development, TCH, The Clearing House, Environment, Bank, Mobile phone

LONDON, Feb. 1, 2023 /PRNewswire/ -- London-based deep tech firm FNA, specialising in advanced network analytics and simulation, has revealed the "powerful liquidity savings" generated by CHIPS, the largest private sector high-value clearing and settlement system in the world operated by The Clearing House, following an independent review.

Key Points: 
  • LONDON, Feb. 1, 2023 /PRNewswire/ -- London-based deep tech firm FNA , specialising in advanced network analytics and simulation, has revealed the "powerful liquidity savings" generated by CHIPS, the largest private sector high-value clearing and settlement system in the world operated by The Clearing House, following an independent review.
  • FNA's review of the liquidity savings mechanism (LSM) utilised by CHIPS confirmed CHIPS is "extremely efficient" in its use of liquidity across all performance metrics, when compared to other large-value payment systems.
  • Its patented liquidity savings algorithm matches and offsets payments continually, resulting in a more efficient settlement process.
  • Not only has this validated CHIPS' liquidity efficiency, but also provided TCH with opportunities to improve their system further".

Independent review by network analytics and simulation firm FNA reveals "powerful liquidity savings" generated by CHIPS settlement algorithm

Retrieved on: 
Wednesday, February 1, 2023
CHIPS, Private sector, School corporal punishment, Clearing house, FNA, Literature, Leg, LSM, Senior, USD, New product development, TCH, The Clearing House, Environment, Bank, Mobile phone

LONDON, Feb. 1, 2023 /PRNewswire/ -- London-based deep tech firm FNA, specialising in advanced network analytics and simulation, has revealed the "powerful liquidity savings" generated by CHIPS, the largest private sector high-value clearing and settlement system in the world operated by The Clearing House, following an independent review.

Key Points: 
  • LONDON, Feb. 1, 2023 /PRNewswire/ -- London-based deep tech firm FNA , specialising in advanced network analytics and simulation, has revealed the "powerful liquidity savings" generated by CHIPS, the largest private sector high-value clearing and settlement system in the world operated by The Clearing House, following an independent review.
  • FNA's review of the liquidity savings mechanism (LSM) utilised by CHIPS confirmed CHIPS is "extremely efficient" in its use of liquidity across all performance metrics, when compared to other large-value payment systems.
  • Its patented liquidity savings algorithm matches and offsets payments continually, resulting in a more efficient settlement process.
  • Not only has this validated CHIPS' liquidity efficiency, but also provided TCH with opportunities to improve their system further".

CAI Awarded Prestigious Public Affairs Council Award for Condominium Safety Policy Response and Initiatives

Retrieved on: 
Thursday, February 9, 2023
Fortune 500, Policy, Brilliance Auto Group, Rapids, Public policy, Education, Housing, Safety, Debbie Wasserman Schultz, Feeding America, Memory, CAI, Church, Government, Community Associations Institute, SAFER, Conference, Local government, Trustee, CAE, Public Affairs Council, PCAM, LSM, Organization, PAC, Research, CMCA, Public Affairs Committee (Malawi), Property management, Insurance

Falls Church, Va., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Community Associations Institute (CAI) is honored to receive the 2022 Lobbying Strategy Innovation Award for its condominium safety policy response and initiatives by the Public Affairs Council (PAC).

Key Points: 
  • Falls Church, Va., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Community Associations Institute (CAI) is honored to receive the 2022 Lobbying Strategy Innovation Award for its condominium safety policy response and initiatives by the Public Affairs Council (PAC).
  • Following the tragic partial collapse of Champlain Towers South condominium in Surfside, Fla., in June 2021, CAI released its Condominium Safety Public Policy Report .
  • The Condominium Safety Public Policy Report provides extensive policy positions and recommendations in reserve studies and funding, building maintenance, and structural integrity.
  • For more information on CAI’s condominium safety policy response and resources to the tragic Champlain Towers South condominium collapse, visit www.condosafety.com .

Ace Vision Group Appoints Healthcare Veterans to Lead Business Development and Commercial Teams

Retrieved on: 
Thursday, January 19, 2023
Dynamic range, Ophthalmology, Presbyopia, Alcon, Bascom Palmer Eye Institute, Laser, DPT, Marketing, AVG, Therapy, Patient, Allergan, D1 Capital Partners, Eye, LSM, Pharmaceutical industry, Management, George Frantzis

BOSTON, Jan. 19, 2023 /PRNewswire/ -- Ace Vision Group, Inc, (AVG) an emerging ophthalmic device company focused on bringing innovative touchless lasers to patients suffering from age-related vision loss and eye diseases impacted by ocular rigidity, announced multiple executive appointments today. John Frantzis will serve as Chief Business Development Officer and Alex Lopez will serve as Chief Commercial Officer effective January 19, 2023.

Key Points: 
  • John Frantzis will serve as Chief Business Development Officer and Alex Lopez will serve as Chief Commercial Officer effective January 19, 2023.
  • "I have great respect for the accomplishments of both Mr. John Frantzis and Mr. Alex Lopez in each of their longstanding careers in healthcare.
  • As Chief Business Development Officer, Frantzis will lead AVG 's strategic venture capital funding efforts, global business development, distribution, and sales.
  • "My longstanding experience in ophthalmology combined with my experience in aesthetics is perfectly suited to support the corporate and commercial vision of AVG."

Axcella Announces Program Reprioritization and Corporate Restructuring

Retrieved on: 
Thursday, December 15, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Biotechnology, Therapy, Security (finance), COVID-19, Homeostasis, Recurrence, Fatigue, IND, Regulation, Patient, Science, NASH, COVID, Non-alcoholic fatty liver disease, File, Compte rendu, Disclosure, Disease, FDA, Emms, FAQ, Hinshaw, Risk, Clinical trial, LSM, Safety, Regulation Fair Disclosure, OHE, EMM, Pharmaceutical industry, Long COVID

Axcella will reprioritize its efforts to focus on the significant unmet need and opportunity presented by Long COVID.

Key Points: 
  • Axcella will reprioritize its efforts to focus on the significant unmet need and opportunity presented by Long COVID.
  • Axcella is engaged in ongoing and productive reviews with regulators in the U.S. and Europe, and the company is aiming to advance its Long COVID Fatigue program into a potential registration trial.
  • Axcella will be discontinuing its ongoing Phase 2b clinical trial of AXA1125 in NASH, while keeping the option to revisit this program should resource availability change.
  • In September, Axcella reported positive data from a preplanned interim analysis from their trial of AXA1125 in NASH.

Imbrium Therapeutics Presents Results of a Phase 2 Study of Sunobinop at 33rd American Academy of Addiction Psychiatry Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Mental Health, Clinical Trials, Crave, Doctor of Pharmacy, Sleep, Maintenance, Therapy, Interstitial, Physician, M.A, AAAP, Addiction psychiatry, Conditional sentence, Polysomnography, AUD, Central nervous system, Eileen Brooke, American Academy, PSG, Patient, Prevalence, Somnolence, Alcoholism, Architecture, FDA, Peripheral nervous system, Pain, CI, Wakefulness, Journal of Medicinal Chemistry, NOP, PACS, LSM, Safety, Gene–environment correlation, Preclinical development, Overactive bladder, Anxiety, American Academy of Addiction Psychiatry, Kolla, Pharmaceutical industry, Mare Imbrium, Insomnia

The data were presented in a poster presentation (#76) at the 33rd Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry (AAAP).

Key Points: 
  • The data were presented in a poster presentation (#76) at the 33rd Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry (AAAP).
  • Sunobinop is an internally discovered oral compound being evaluated as a potential treatment for multiple disorders including insomnia during recovery from AUD.
  • The Phase 2 randomized, double-blind, multi-center, placebo-controlled, parallel-group clinical study enrolled 114 people experiencing insomnia during recovery from AUD.
  • Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics.

WTW collaboration with Liberty Specialty Markets and Markel moves insurance industry closer to digital-first marketplace

Retrieved on: 
Thursday, November 17, 2022
WTW, Markel Corporation, Digital, LSM, Risk, Insurance, Workforce, Automation, Shoulder, Global production network, Risk management, Financial services

LONDON, Nov. 17, 2022 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, has announced a new collaboration with insurers Liberty Specialty Markets (LSM) and Markel, launching the pilot phase of an innovative digital commercial insurance platform.

Key Points: 
  • LONDON, Nov. 17, 2022 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, has announced a new collaboration with insurers Liberty Specialty Markets (LSM) and Markel, launching the pilot phase of an innovative digital commercial insurance platform.
  • Developed in collaboration with LSM and Markel, this new platform signals a step-change in digital trading, especially in a market as complex as London.
  • At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital.
  • Liberty Specialty Markets offers specialty and commercial insurance and reinsurance products across key UK, European, Middle East, US, Bermuda, Asia Pacific & Latin America markets.

Understanding the Link Between NAFLD and Diabetes: Echosens Points to New AACE Guideline Supporting FibroScan as Key Component of Type 2 Diabetes Management

Retrieved on: 
Thursday, November 17, 2022
Software, Managed Care, Hardware, Data Management, Biometrics, Medical Devices, Technology, Infectious Diseases, Hospitals, Practice Management, Health, Diabetes, Type 2 diabetes, Type 2, Fibrosis, CAP, Medicaid, AHA, Cirrhosis, NASH, Patient, Fatty liver disease, Liver disease, Elastography, AACE, Obesity, Medicare, American Gastroenterological Association, Diet, Woman, NAFLD, Person, Physician, Guideline, Chronic liver disease, Diabetes, Public health, LSM, Diagnosis, Risk, American Heart Association, Steatosis, T2D, Endocrinology, AGA, Health, Incidence, Pharmaceutical industry, Medical imaging

These new guideline recommendations as reported in AACE reinforce the use of FibroScan solutions for the management of patients with NAFLD throughout the patient care continuum.

Key Points: 
  • These new guideline recommendations as reported in AACE reinforce the use of FibroScan solutions for the management of patients with NAFLD throughout the patient care continuum.
  • The recommendations are a breakthrough in early diagnosis and management of patients with NAFLD, targeting primary care and endocrinology clinical settings.
  • American Diabetes Month demonstrates an effective public health outreach effort to increase awareness and advocacy for patients touched by diabetes and other related diseases.
  • Type 2 diabetes mellitus and NAFLD frequently co-exist in patients and share the same pathophysiological manifestations, including hepatic steatosis and fibrosis.

Axcella Reports Third Quarter Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 1, 2022
COVID-19, Infectious Diseases, Finance, Clinical Trials, Professional Services, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Homeostasis, Security (finance), Regulation Fair Disclosure, Fatty liver disease, LSM, Disclosure, Flagship Pioneering, Board of directors, Cirrhosis, COVID, Inflammation, Leadership, U.S. Securities and Exchange Commission, Regulation, SEC, Board, D, IND, Fibrosis, COVID-19, FAQ, Securities Act of 1933, File, EMM, KPA, Research, ALT, Emms, NASH, Metabolism, Private Securities Litigation Reform Act, Company, Therapy, Review, FDA, Patient, Compte rendu, Fatigue, Pharmaceutical industry, Long COVID

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.

Key Points: 
  • Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.
  • This has been an extremely exciting period for Axcella, said Bill Hinshaw President and Chief Executive Officer of Axcella.
  • Clinical Results in the Quarter:
    The quarter saw progress in the clinical development of AXA1125, an orally delivered potent and safe compound addressing two very large markets: Long-COVID and NASH.
  • This included the release of top-line results in Long COVID and an interim analysis of the Phase 2b EMMPACT trial in NASH.